1. Prophylactic Effect of Amiodarone Infusion on Reperfusion Ventricular Fibrillation After Release of Aortic Cross-Clamp in Patients with Left Ventricular Hypertrophy Undergoing Aortic Valve Replacement: ARandomized Controlled Trial
- Author
-
Shin Kagaya, Norikatsu Mita, Masataka Kuroda, and Sohtaro Miyoshi
- Subjects
Male ,medicine.medical_specialty ,Lidocaine ,Amiodarone ,Myocardial Reperfusion ,030204 cardiovascular system & hematology ,Left ventricular hypertrophy ,03 medical and health sciences ,0302 clinical medicine ,Double-Blind Method ,Aortic valve replacement ,030202 anesthesiology ,Internal medicine ,medicine ,Humans ,Prospective Studies ,Infusions, Intravenous ,Aged ,Aged, 80 and over ,Heart Valve Prosthesis Implantation ,business.industry ,Aortic Valve Stenosis ,Middle Aged ,medicine.disease ,Cardiac surgery ,Stenosis ,Aortic cross-clamp ,Treatment Outcome ,Anesthesiology and Pain Medicine ,Ventricular Fibrillation ,Ventricular fibrillation ,cardiovascular system ,Cardiology ,Female ,Hypertrophy, Left Ventricular ,Post-Exposure Prophylaxis ,Cardiology and Cardiovascular Medicine ,business ,Anti-Arrhythmia Agents ,medicine.drug - Abstract
To investigate whether prophylactic amiodarone infusion prevents ventricular fibrillation after aortic cross-clamp release and attenuates cytokine production in patients with left ventricular hypertrophy undergoing cardiac surgery.Prospective, randomized controlled trial.A public hospital.The study comprised 68 patients undergoing aortic valve replacement for severe aortic stenosis.Patients were randomly assigned to receive a 150mg bolus then 30mg/h continuous infusion of amiodarone (amiodarone group) or a 1 mg/kg bolus then 1 mg/kg/h continuous infusion of lidocaine (lidocaine group). The primary outcome was the ventricular fibrillation incidence rate after aortic cross-clamp release. Secondary outcomes included perioperative serum interleukin-6 and tumor necrosis factor-alpha levels.The ventricular fibrillation incidence rate was significantly lower in the amiodarone than in the lidocaine group (20.6% v 50%, relative risk 0.41; 95% confidence interval [CI] 0.20-0.86; p = 0.021). Interleukin-6 levels 1hour after aortic cross-clamp release and at intensive care unit admission were significantly lower in the amiodarone than in the lidocaine group (geometric mean [95% CI] 117.4pg/mL [87.1-158.4] v 339.5pg/mL [210.6-547.2]; p0.01 and 211.1pg/mL [162.8-73.6] v 434.1pg/mL [293.7-641.5]; p0.01, respectively). Tumor necrosis factor-alpha levels 1hour after aortic cross-clamp release were significantly lower in the amiodarone than in the lidocaine group (geometric mean [95% CI] 1.624pg/mL [1.359-1.940] v 2.283pg/mL [1.910-2.731]; p = 0.02).Amiodarone prevented reperfusion ventricular fibrillation in patients with left ventricular hypertrophy undergoing aortic valve replacement to a greater extent than did lidocaine. Furthermore, amiodarone inhibited postoperative interleukin-6 and tumor necrosis factor-alpha production.
- Published
- 2019
- Full Text
- View/download PDF